After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...